Rahme GJ, Gaskell E, Bernstein BE. GABPβ1L Wakes Up TERT. Cancer Cell. 2018;34(3):358-360. doi:10.1016/j.ccell.2018.08.011
Godlewski J, Ferrer-Luna R, Rooj AK, et al. MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. Stem Cell Reports. 2017;8(6):1497-1505. doi:10.1016/j.stemcr.2017.04.024
Wang H, Pan JQ, Luo L, et al. NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma. Mol Cancer. 2015;14:2. doi:10.1186/1476-4598-14-2
Miller TE, Liau BB, Wallace LC, et al. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. 2017;547(7663):355-359. doi:10.1038/nature23000
Yu D, Khan OF, Suvà ML, et al. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A. 2017;114(30):E6147-E6156. doi:10.1073/pnas.1701911114
Chow RD, Guzman CD, Wang G, et al. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci. 2017;20(10):1329-1341. doi:10.1038/nn.4620
Goods BA, Hernandez AL, Lowther DE, et al. Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. PLoS One. 2017;12(9):e0181538. doi:10.1371/journal.pone.0181538
Stein S, Zhao R, Haeno H, Vivanco I, Michor F. Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol. 2018;14(1):e1005924. doi:10.1371/journal.pcbi.1005924
Cimino PJ, Kim Y, Wu HJ, et al. Increased expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev. 2018;32(7-8):512-523. doi:10.1101/gad.312157.118
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372(26):2481-98. doi:10.1056/NEJMoa1402121